Precise immunomodulation by mesenchymal stem cells mitigates hepatitis B virus-specific CD8⁺ T cell-mediated acute liver injury without compromising viral clearance.

Xingxing Li, Zhiwei Li, Qibin Liao, Yanhong Huang, Shumin Liao, Liang Li

Abstract read

In one paragraph

Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xingxing Li *Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern University of Science and Technology, Shenzhen, 518000, China.

Zhiwei Li *Department of Hepato-Biliary Surgery, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Guangdong, Shenzhen, China.

Qibin Liao *State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Yanhong HuangDepartment of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern University of Science and Technology, Shenzhen, 518000, China.

Shumin LiaoDepartment of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern University of Science and Technology, Shenzhen, 518000, China. liaosm2022@sustech.edu.cn.

Liang LiDepartment of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern University of Science and Technology, Shenzhen, 518000, China. lil@sustech.edu.cn.

Funding

the National Key Research and Development Program of China 2022YFC2304400 and 2022YFC2304401

6 · The paper itself

Abstract

Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is associated with a high mortality rate. Although mesenchymal stem cell (MSC) therapy markedly improves liver function and survival in patients with HBV-ACLF, it remains unclear whether the immunomodulatory effects of MSCs suppress antiviral CD8⁺ T cell function and trigger HBV reactivation. Here, we developed a novel in vitro HBV-specific CD8⁺ T cell-mediated acute liver injury organoid model, which was co-cultured with either menstrual blood-derived MSCs (MenSCs) or umbilical cord-derived MSCs (UC-MSCs). We found that both MenSCs and UC-MSCs coordinate liver repair and antiviral immunity through precise immunomodulation, primarily via paracrine signaling. Both MSC types significantly downregulated pro-inflammatory (IFN-γ, TNF-α, IL-8, and CXCL10) and apoptosis-related genes (FasL and CASP7), while promoting hepatic regeneration through IL-6 and HGF upregulation, without compromising CD8⁺ T cell-mediated HBV clearance. This study provides critical insights into the safety of MSC therapy for HBV-ACLF.

Indexed as

CD8-Positive T-LymphocytesHepatitis BHepatitis B virusImmunomodulationLiverMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsCoculture TechniquesFemaleHumansAcute liver injury modelCell therapyHBV-specific CD8⁺ T cellsImmunomodulationLiver organoidsMesenchymal stem cells

Identifiers

PMID42920175

DOI10.1016/j.tips.2020.06.009

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.